Skip to main content
Equibles
DFTX logo

DFTX · Definium Therapeutics, Inc. · Documents

Track DFTX — free

Use DFTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DFTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$33.00 -1.47 (-4.26%) At close · Nov 12 Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$4.52B
Shares
136.90M
Volume · Nov 12 1.2M Avg daily vol (3M) 2M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $183.79M 10-K filed Feb 26, 2026 Quarterly report New FY2026 Q3 Net loss $50.96M 10-Q filed Nov 9, 2026 Latest results New Financial results 8-K filed Nov 9, 2026 Earnings call New Q3 2026 earnings call Held Nov 9, 2026
2026
Nov 10
Investor event
Three positive DT120 studies precede planned FDA NDA

Definium Therapeutics reported three positive phase three readouts for DT120—two in GAD and one in MDD—and plans to submit an NDA to FDA in the first half of next year for both indications.

3 source passages
Happy to be here with Dan Carlin, Chief Medical Officer of Definium Therapeutics. And we have now read out three phase three studies with DT120, two in GAD and one in MDD. And on the back of those three positive phase three readouts, we will be submitting an NDA to FDA in the first half of next year, and we intend to find a path to submit for both GAD and MDD. Open the document at this passage
Nov 9
Earnings call
DT120 heads toward 2027 NDA after three positive studies

Definium Therapeutics reported three positive phase 3 studies for DT120 in GAD and MDD, plans an NDA filing in the first half of 2027, and expects approximately $1.05 billion in cash and investments to fund operations into 2030.

4 source passages
Definium Therapeutics' third quarter 2026 financial results and recent Business Highlights conference call We have three positive phase 3 studies for DT120 and GAD and MDD, breakthrough therapy designations in both indications, and we remain on track for NDA filing in the first half of 2027. As of September 30th, 2026, cash, cash equivalents, and investments were approximately $1.05 billion, compared with $411.6 million as of December 31st, 2025. Based on our current operating plan and anticipated milestones, we expect these resources to fund planned operations into 2030. Open the document at this passage
Sep 8
Current report 8-K
Other events AI summary on its way
May 19
Current report 8-K
Other events AI summary on its way
May 12
Current report 8-K
Other events AI summary on its way
Apr 27
Proxy statement DEF 14A Meeting Jun 11, 2026
Proxy statement AI summary on its way
Apr 22
Current report 8-K
Other events AI summary on its way
Feb 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $183.79M Diluted EPS -$2.06
2025
Showing 1–50 of 207 documents
Key facts CIK 1813814 CUSIP 24477V105 13F (30d) 192 filings 190 filers Visit website Investor relations